View examples of how we address the unique need of every research question to deliver innovative, multidimensional solutions to convey the value of healthcare innovations. Download our posters from recent conferences.
| ISPOR 2020 Posters | Link |
|---|---|
| Humanistic Burden Associated with Depression and Anxiety Among Adults with Non-Communicable Chronic Diseases (NCCDs) in the United States | Download |
| Budget Impact Analysis of Introduction of Rituximab Biosimilar in the United States from a Payer Perspective | Download |
| Comparison of Treatment Adherence And Persistence with Edoxaban Versus Apixaban, Dabigatran, Rivaroxaban, and Vitamin K Antagonist in Non-Valvular Atrial Fibrillation Patients in Germany: A Propensity Matched Cohort Study | Download |
| Budget Impact Analysis of Introduction of Bevacizumab Biosimilar in the United States from a Payer Perspective | Download |
| Budget Impact Analysis of Introduction of IV Trastuzumab Biosimilar (Trastuzumab-qyyp) from Buyer and Payer Perspectives in France | Download |
| Real-World Economic and Clinical Outcomes Associated with Current Hemostatic Matrix Use in Spinal Surgery | Download |
| Real-World Economic and Clinical Outcomes Associated with Current Hemostatic Matrix Use in Cardiovascular Surgery | Download |
| ISPOR Europe Symposium | Link |
|---|---|
| SURVIVAL MODELLING: TRENDS AND INNOVATIONS | Download |
| ISPOR HEOR Theater | Link |
|---|---|
| COMMUNICATING VALUE TO DECISION-MAKERS: WHAT’S YOUR PROGNOSIS? | Download |
| ISPOR Europe 2019 Posters | Link |
|---|---|
| COST-EFFECTIVENESS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB COMPARED TO SUNITINIB IN THE FIRST-LINE TREATMENT OF ADVANCED OR METASTATIC INTERMEDIATE- OR POOR-RISK RENAL CELL CARCINOMA IN ITALY | Download |
| COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB + IPILIMUMAB VERSUS SUNITINIB IN THE FIRST-LINE TREATMENT OF ADVANCED OR METASTATIC INTERMEDIATE- OR POOR-RISK RENAL CELL CARCINOMA IN SPAIN | Download |
| COST-EFFECTIVENESS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB COMPARED TO SUNITINIB FOR THE FIRST-LINE TREATMENT OF ADVANCED/METASTATIC INTERMEDIATE- OR POOR-RISK RENAL CELL CARCINOMA IN SWITZERLAND | Download |
| UPDATED NETWORK META-ANALYSIS OF TREATMENTS IN FIRST-LINE ADVANCED/METASTATIC INTERMEDIATE- OR POOR-RISK RENAL CELL CARCINOMA | Download |
| STABILITY OF LIFETIME OVERALL SURVIVAL ESTIMATES OF NIVOLUMAB+IPILIMUMAB IN FIRST-LINE ADVANCED/METASTATIC INTERMEDIATE- OR POOR-RISK RENAL CELL CARCINOMA | Download |
| COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB FOR THE FIRST-LINE TREATMENT OF ADVANCED/METASTATIC RENAL CELL CARCINOMA IN GREECE | Download |
| COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB VERSUS SUNITINIB FOR THE FIRST-LINE TREATMENT OF INTERMEDIATE- TO POOR-RISK ADVANCED RENAL CELL CARCINOMA IN FRANCE | Download |
| USING MACHINE LEARNING FOR EFFICIENCY IMPROVEMENTS IN SYSTEMATIC LITERATURE REVIEWS OF CLINICAL EFFICACY AND SAFETY | Download |
| BAYESIAN MODEL AVERAGING FOR EXTRAPOLATING SURVIVAL: A PAN-TUMOR PERSPECTIVE ON NIVOLUMAB AND IPILIMUMAB | Download |
| MODELING THE SURVIVAL BENEFIT OF IMMUNO-ONCOLOGIC THERAPY: A REVIEW OF METHODS USED IN NICE SINGLE TECHNOLOGY APPRAISALS | Download |
| COMPARISON OF TIME TO REIMBURSEMENT RECOMMENDATIONS OF (ORPHAN-) ONCOLOGY DRUGS IN EUROPE | Download |
| MAXIMUM LIKELIHOOD ESTIMATION TO QUANTIFY THE IMPACT OF TREATMENT RESPONSE ON SURVIVAL OUTCOMES | Download |
| BALANCING GLOBAL HTA REQUIREMENTS FOR LITERATURE REVIEWS ACROSS EUROPE, NORTH AMERICA, AND ASIA | Download |
| IMPROVING THE ACCURACY AND REDUCING UNCERTAINTY OF PROBABILISTIC PARTITIONED SURVIVAL ANALYSES, BY CONSIDERING THE RELATIONSHIP BETWEEN PFS AND OS | Download |
| AMCP Nexus 2019 | Link |
|---|---|
| CHARACTERISTICS, SYSTEMIC TREATMENTS AND OUTCOMES IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA: A SYSTEMATIC LITERATURE REVIEW | Download |